SCIENCE DRIVEN
PATIENT FOCUSED
As a world leader in RNA-targeted gene therapy, Locana is committed to bring life-changing therapies to patients with severe conditions based on the core values that drive our work every day—trust, collaboration, adaptability, dedication and excellence.
SCIENCE DRIVEN
PATIENT FOCUSED
As a world leader in RNA-targeted gene therapy, Locana is committed to bring life-changing therapies to patients with severe conditions based on the core values that drive our work every day—trust, collaboration, adaptability, dedication and excellence.

Experienced leadership team

Meet our management team with world recognized expertise in RNA biology, RNA-mediated disease and gene therapy. Together with our top-tier Board of Directors, we are excited to be developing a powerful new generation of genetic medicines.
James Burns, PhD
Chief Executive Officer
Board Member
James Burns, PhD
Chief Executive Officer
Board Member
James Burns joined Locana in December 2019 as the CEO and Director of the Board. Dr. Burns joins us from Casebia, where he served as the chief executive officer and led the team in discovering and developing new CRISPR/Cas9-based breakthrough therapeutics to treat blood disorders, blindness and heart disease. Prior to Casebia, he spent the bulk of his career at Sanofi-Genzyme, where he held several leadership roles with increasing responsibility, including North America Site head for R&D where he coordinated R&D operations across key therapeutic areas. Dr. Burns is a former board member of MassBio, a member of the U.S. National Academy of Engineering and is a member of the External Advisory Committee for the BioMedical Engineering Department at Boston University. He also served as the industry representative for the Food and Drug Administration General Plastic Surgery Panel. Dr. Burns earned a Bachelor of Science degree in biology from Purdue University and Master of Science and Doctorate degrees in bioengineering from the University of Illinois-Chicago, where his thesis work focused on drug delivery. Following his graduate studies, he was a post-doctoral researcher at the University of Florida.
Kathie Bishop, PhD
Chief Scientific Officer
Kathie Bishop, PhD
Chief Scientific Officer
Kathie M. Bishop, Ph.D. joined Locana in August 2019 as Chief Scientific Officer. Dr. Bishop has 20 years experience in leading translational research and drug development, with a focus on novel therapeutics in neurological and rare diseases. She was previously CSO at Otonomy, where she led preclinical and clinical development of a pipeline of neurotology programs. Before that, she was CSO of Tioga Pharmaceuticals. From 2009 to 2015, Dr. Bishop served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development. At Ionis, she led translation and development of multiple programs in the neurology franchise including leading the development and clinical trials for SPINRAZA™ (nusinersen), the first approved treatment for patients with spinal muscular atrophy, Dr. Bishop also served in research and development leadership roles from to 2001 to 2009 at Ceregene, a company focused on the development of AAV-based gene therapy products for the treatment of neurodegenerative and retinal disorders. She conducted post-doctoral work at the Salk Institute for Biological Studies and obtained a Ph.D. in Neuroscience from the University of Alberta.
Micah Mackison
Chief Business Officer
Micah Mackison
Chief Business Officer
Micah joined Locana in April 2020 as Chief Business Officer. He joins us from Assembly Biosciences, where he served as Senior Vice President, Corporate Development and Strategy leading business development efforts since 2015. Prior to Assembly, he was Senior Director, Corporate Investment at Jabil Healthcare & Life Sciences, where he led healthcare transactions. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, focused on neuroscience. Prior to the acquisition by Lundbeck, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a rare disease, neuroscience company that launched the first product for Huntington’s Disease. Micah previously held financial roles at Eli Lilly and Pfizer. Micah earned a Bachelor of Science degree in Finance from Indiana University.
Holly Winter
Vice President, Human Resources
Holly Winter
Vice President, Human Resources
Holly Winter joined Locana in April 2020 as Vice President, Human Resources. Holly has over 20 years of human resources experience including most recently Vice President, Human Resources at aTyr Pharma, where she worked extensively with the leadership team to define aTyr’s human resources strategy, grow the company and act as part of the IPO team. Holly has also held human resource leadership roles at Vertex Pharmaceuticals and Aurora Biosciences, and began her career in human resources at as subsidiary of Ford Motor Company. Holly graduated from California State University, Long Beach, with a degree in Political Science and studied German and English languages at the University of Salzburg, Salzburg, Austria. Holly works closely with the Locana team to establish values and practices directed towards building a positive and productive work culture.

Board of Directors

Tom Daniel, MD
Venture Partner, Arch Venture Partners
Chairman of the Board
James Burns, PhD
Chief Executive Officer
Board Member
Cayce Denton, MBA
Director, Temasek Holdings
Board Member
Jean George, MBA
General Partner, Lightstone
Board Member
Gene Yeo, PhD, MBA
Co-Founder and Scientific Advisor
Board Member
Jeffrey M. Ostrove, PhD
Former Chief Executive Officer
Independent Board Member

Investors

We are proud to have earned the confidence and support of the following key investors.

Contact US

Locanabio, Inc.
3545 John Hopkins Court
Suite 200
San Diego, CA 92121

858.285.4000
info@locanabio.com